Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04 2024 - 4:05PM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced
that the company approved the grant of equity awards to one new
employee with a grant date of April 1, 2024, as equity inducement
awards outside of the company's 2017 Stock Incentive Plan (but
under the terms of the 2020 Inducement Stock Incentive Plan) and
material to the employees’ acceptance of employment with the
company. The equity awards were approved in accordance with Nasdaq
Listing Rule 5635(c)(4).
The employee received 1,215 restricted stock units (RSUs). Each
RSU will vest as to 25% of the shares underlying the RSU award on
the first anniversary of the grant date and as to an additional 25%
of the shares underlying the RSU award annually thereafter, subject
to each such employee's continued employment on each vesting
date.
About ApellisApellis Pharmaceuticals, Inc. is a
global biopharmaceutical company that combines courageous science
and compassion to develop life-changing therapies for some of the
most challenging diseases patients face. We ushered in the first
new class of complement medicine in 15 years and now have two
approved medicines targeting C3. These include the first-ever
therapy for geographic atrophy, a leading cause of blindness around
the world. We believe we have only begun to unlock the potential of
targeting C3 across serious retinal, rare, and neurological
diseases. For more information, please
visit http://apellis.com or follow us
on Twitter and LinkedIn.
Apellis Forward-Looking StatementStatements in
this press release about future expectations, plans and prospects,
as well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements regarding the safety profile of SYFOVRE. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including whether the benefit/risk profile of SYFOVRE
following these reported events will impact our commercialization
efforts; whether SYFOVRE will receive approval from foreign
regulatory agencies for GA when expected or at all, including the
impact of the reported events of retinal vasculitis on the
likelihood and timing of such approvals; and other factors
discussed in the “Risk Factors” section of Apellis’ Annual Report
on Form 10-K with the Securities and Exchange Commission on
February 21, 2023 and the risks described in other filings that
Apellis may make with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Apellis specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.Media
Contact:Lissa Pavlukmedia@apellis.com617.977.6764
Investor Contact:Meredith
Kayameredith.kaya@apellis.com617.599.8178
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Jul 2023 to Jul 2024